drugset
drugset / Trial / NCT01458769

Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz

NCT01458769 ↗

Phase 1 Completed 47 enrolled Concert Pharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of isotopologs of Atazanavir both as single agents and as combinations.

Timeline

Start
2010-12
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 400 mg Oral
Comparator Atazanavir Other / unclassified 600 mg Oral
Comparator C-10276 Unknown 200 mg Oral
Comparator C-10276 Unknown 300 mg Oral
Comparator C-10276 Unknown 400 mg Oral
Comparator C-10276 Unknown 600 mg Oral
Comparator C-10297 Unknown 200 mg Oral
Comparator C-10297 Unknown 400 mg Oral
Comparator C-10297 Unknown 600 mg Oral
Comparator C-10299 Unknown 200 mg Oral
Comparator C-10299 Unknown 400 mg Oral
Comparator C-10299 Unknown 600 mg Oral
Subject CTP-518 Unknown 100 mg Oral

Indications

No indication recorded.